Listen and follow our podcasts on:

This educational programme is supported by an Independent Educational Grant from Menarini Stemline Oncology

In this podcast series, Prof. Shaheenah Dawood and Assoc. Prof. Rena Callahan discuss oral SERDs for ER+/HER2- advanced or metastatic breast cancer.

 

Episode 1: Oral SERDs in ER+ breast cancer: efficacy, safety and treatment landscape

The experts explore the efficacy and safety profiles of oral SERDs and their place in the treatment landscape, and discuss how to optimise treatment selection and make appropriate sequencing decisions.

 

Episode 2: Oral SERDs in ER+ breast cancer: treatment selection and beyond

A deep-dive into two patient case studies of ER+/HER2- metastatic breast cancer, discussing the intricacies of treatment selection and sequencing to maximise outcomes, current data, and what to consider when adjusting dosage or switching treatments.

 

Episode 3: Oral SERDS in ER+ breast cancer: rare cases & treatment challenges

Prof. Dawood and Assoc. Prof. Callahan discuss the next two patient case studies of ER+/HER2- metastatic breast cancer, each presenting unique and rare situations that shed a light on the challenges confronting healthcare professionals and patients alike.

 

  • Recognise the efficacy and safety profiles of SERDs for patients with advanced or metastatic BC, and understand their place in the treatment landscape for patients with BC
  • Implement optimization of treatment selection, and make the appropriate sequencing decisions
  • Be able to identify and manage adverse events

Shaheenah Dawood is a Consultant medical oncologist and professor in clinical oncology in the United Arab Emirates. She trained in medical oncology at McGill University Hospitals in Canada and subspecialized in breast cancer management at MD Anderson Cancer Center. During her training she was awarded multiple scholar in training awards and ASCO merit awards. She has served as an editorial fellow at the New England Journal of medicine and has an MPH from the Harvard School of Public Health. She has over 100 papers to her credit including 50 peer review original articles, 30 review articles and 12 book chapters. She serves as a reviewer for multiple journals. She currently leads the oncology clinical trials program at Mediclinic City Hospital Dubai. She also serves as president of the Excellence in oncology summit that is held annually in Dubai and is co president of the Asia pacific breast cancer summit (ABCS) and Asia pacific gastrointestinal cancer summit (APGCS). She has also recently launched the international BRCA forum and young womens forum.

Prof. Shaheenah Dawood has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

MSD, Roche, BMS, New Bridge, Novartis, llilly , Pfizer, Caris, Merck, Jaansen, Ipsen,Astrazeneca, Zulleg Pharma

Rena D. Callahan, MD, is Associate Clinical Professor of Health Sciences in the Division of Hematology-Oncology in the Department of Medicine at the University of Los Angeles, California (UCLA) David Geffen School of Medicine. She received her undergraduate degree from Yale University, and her medical degree from the University of Pennsylvania in Philadelphia, before completing an internship and residency in Internal Medicine and a fellowship in Hematology-Oncology at UCLA. Dr Callahan is board-certified in Internal Medicine, Medical Oncology, and Hematology. Dr Callahan is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the American College of Physicians. She has served as principal or sub-investigator for numerous clinical research trials exploring topics related to breast cancer. Dr Callahan is a frequent lecturer on a variety of breast cancer topics and is focused on providing patient centered clinical care in the context of a large clinical practice.

Assoc. Clinical Professor Rena Callahan has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Support provided as a speaker from: Gilead, Lilly, Stemline, Seagen

Listen and follow our podcasts on:

This educational programme is supported by an Independent Educational Grant from Menarini Stemline Oncology

In this podcast series, Prof. Shaheenah Dawood and Assoc. Prof. Rena Callahan discuss oral SERDs for ER+/HER2- advanced or metastatic breast cancer.

 

Episode 1: Oral SERDs in ER+ breast cancer: efficacy, safety and treatment landscape

The experts explore the efficacy and safety profiles of oral SERDs and their place in the treatment landscape, and discuss how to optimise treatment selection and make appropriate sequencing decisions.

 

Episode 2: Oral SERDs in ER+ breast cancer: treatment selection and beyond

A deep-dive into two patient case studies of ER+/HER2- metastatic breast cancer, discussing the intricacies of treatment selection and sequencing to maximise outcomes, current data, and what to consider when adjusting dosage or switching treatments.

 

Episode 3: Oral SERDS in ER+ breast cancer: rare cases & treatment challenges

Prof. Dawood and Assoc. Prof. Callahan discuss the next two patient case studies of ER+/HER2- metastatic breast cancer, each presenting unique and rare situations that shed a light on the challenges confronting healthcare professionals and patients alike.

 

  • Recognise the efficacy and safety profiles of SERDs for patients with advanced or metastatic BC, and understand their place in the treatment landscape for patients with BC
  • Implement optimization of treatment selection, and make the appropriate sequencing decisions
  • Be able to identify and manage adverse events

Shaheenah Dawood is a Consultant medical oncologist and professor in clinical oncology in the United Arab Emirates. She trained in medical oncology at McGill University Hospitals in Canada and subspecialized in breast cancer management at MD Anderson Cancer Center. During her training she was awarded multiple scholar in training awards and ASCO merit awards. She has served as an editorial fellow at the New England Journal of medicine and has an MPH from the Harvard School of Public Health. She has over 100 papers to her credit including 50 peer review original articles, 30 review articles and 12 book chapters. She serves as a reviewer for multiple journals. She currently leads the oncology clinical trials program at Mediclinic City Hospital Dubai. She also serves as president of the Excellence in oncology summit that is held annually in Dubai and is co president of the Asia pacific breast cancer summit (ABCS) and Asia pacific gastrointestinal cancer summit (APGCS). She has also recently launched the international BRCA forum and young womens forum.

Prof. Shaheenah Dawood has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

MSD, Roche, BMS, New Bridge, Novartis, llilly , Pfizer, Caris, Merck, Jaansen, Ipsen,Astrazeneca, Zulleg Pharma

Rena D. Callahan, MD, is Associate Clinical Professor of Health Sciences in the Division of Hematology-Oncology in the Department of Medicine at the University of Los Angeles, California (UCLA) David Geffen School of Medicine. She received her undergraduate degree from Yale University, and her medical degree from the University of Pennsylvania in Philadelphia, before completing an internship and residency in Internal Medicine and a fellowship in Hematology-Oncology at UCLA. Dr Callahan is board-certified in Internal Medicine, Medical Oncology, and Hematology. Dr Callahan is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the American College of Physicians. She has served as principal or sub-investigator for numerous clinical research trials exploring topics related to breast cancer. Dr Callahan is a frequent lecturer on a variety of breast cancer topics and is focused on providing patient centered clinical care in the context of a large clinical practice.

Assoc. Clinical Professor Rena Callahan has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Support provided as a speaker from: Gilead, Lilly, Stemline, Seagen

Programme summary
Listen to the podcast now
Other episodes of this series
Oral SERDs in ER+ breast cancer

Oral SERDs in ER+ breast cancer

Episode 1: Efficacy, safety and treatment landscape

Oral SERDs in ER+ breast cancer

Oral SERDs in ER+ breast cancer

Episode 2: Treatment selection and beyond

Current Episode
Oral SERDS in ER+ breast cancer

Oral SERDS in ER+ breast cancer

Episode 3: Rare cases & treatment challenges

Share this programme
This educational programme is supported by an Independent Educational Grant from Menarini Stemline Oncology
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Menarini Stemline Oncology
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
BREAST CANCER CONNECT

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Menarini Stemline Oncology, AstraZeneca and Thermo Fisher Scientific.

Meet the experts Independent IME approved
Programme summary
  • clock Duration MIN
  • clock Language(s) flag
Listen to the podcast now
Other episodes of this series
Oral SERDs in ER+ breast cancer

Oral SERDs in ER+ breast cancer

Episode 1: Efficacy, safety and treatment landscape

Oral SERDs in ER+ breast cancer

Oral SERDs in ER+ breast cancer

Episode 2: Treatment selection and beyond

Current Episode
Oral SERDS in ER+ breast cancer

Oral SERDS in ER+ breast cancer

Episode 3: Rare cases & treatment challenges

Share this programme
This educational programme is supported by an Independent Educational Grant from Menarini Stemline Oncology
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Menarini Stemline Oncology
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
BREAST CANCER CONNECT

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Menarini Stemline Oncology, AstraZeneca and Thermo Fisher Scientific.

Meet the experts Independent IME approved

Other programmes of interest

podcast Video podcast
Oncology 
Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

Experts
Dr Carlos Barrios, Prof. Gary Tse, Oncology Brothers (Moderators)
Endorsed by
Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Daiichi Sankyo 
eks
EKS / On-demand webinar
Oncology 
Multiple Myeloma: Is it time to rethink how we sequence treatments?

On-demand materials from an Experts Knowledge Share event

Experts
Prof. Karthik Ramasamy, Dr Joshua Richter, Dr Faisal Basheer, Dr Andrew Charlton
  • download Downloadable
    Resources
  • clock 80 MIN
  • calendar Mar 2026

This programme has been sponsored by Menarini Stemline and is intended for HCPs in the UK only    MAT-GB-SEL-00774
conference-update Conference update

Episode

2

of 2

episode
Oncology Rare diseases Endocrinology 
Actualités du Congrès l’ENETS 2026

Points de vue d’experts sur les dernières données concernant le cancer neuroendocrinien

Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand
  • clock 5 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Cette vidéo est soutenue par une subvention indépendante à visée éducative d’Ipsen.  Les contenus publiés sur ce site internet sont sous la responsabilité de leurs auteurs. Certaines données scientifiques publiées sur ce site sont susceptibles de ne pas être validées par la commission d’Autorisation de Mise sur le Marché, et ne doivent pas être mises en pratique. Elles doivent être lues et comprises avec le plus grand discernement et sont données dans leur cadre de la diffusion de l’information sur l’état actuel de la recherche auprès de la communauté scientifique internationale  
conference-update Conference update

Episode

1

of 2

episode
Oncology Rare diseases Endocrinology 
Update from ENETS 2026

Experts share their views on latest data in neuroendocrine cancer

Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand
  • clock 5 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.
patient-support Patient Support
Oncology Hemato-oncology Pediatrics 
Personalised treatment in childhood cancer: A journey through NTRK fusion testing

Experts
Linet Menachery
Endorsed by
NTRKers ICAN international cancer advocacy network Biomarker Collaborative
  • clock 4 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.